Evaluation of Cystatin-C as a Biomarker of Renal Function in Type-2 Diabetes Mellitus

Dr. Shabnam S; Dr. C R Mallikarjun; Dr. Peersab M Pinjar

Volume : VIII, Issue : XII, December - 2019

Evaluation of Cystatin-C as a Biomarker of Renal Function in Type-2 Diabetes Mellitus

Dr. Shabnam S, Dr. C R Mallikarjun, Dr. Peersab M Pinjar

Abstract :

Introduction: Diabetes has become the most common single cause of End Stage Renal Disease (ESRD) in most countries. About 20–30% of patients with diabetes develop evidence of nephropathy. Cystatin–C has been identified as a promising new biomarker for the detection of renal damage and is more sensitive than creatinine. Material and Method: In this study, 50 proven cases of Type–2 Diabetic patients and an equal number of age and sex matched healthy controls were included during the study period from November–2013 to August–2015. Result: The serum concentrations of FBG, Creatinine and Cystatin–C were increased and eGFR was decreased in Type–2 Diabetic patients as compared to healthy controls (p, < 0.001). We also found that there was a significant positive correlation of serum cystatin–C with FBG and Creatinine and negative correlation with eGFR in Type–2 Diabetes patients. Conclusion: This study concludes that cystatin–C is superior for renal glomerular function assessment in a well–defined patient group, its measurement may be recommended in the routine management of diabetic patients.